New sedatives and analgesic drugs for gastrointestinal endoscopic procedures

Jae Min Lee¹, Yehyun Park², Jin Myung Park³, Hong Jun Park⁴, Jun Yong Bae⁵, Seung Young Seo⁶, Jee Hyun Lee⁷, Hyung Ku Chon⁸, Jun-Won Chung⁹, Hyun Ho Choi¹⁰, Jun Kyu Lee¹¹, Byung-Wook Kim¹², Endoscopic Sedation Committee of the Korean Society of Gastrointestinal Endoscopy

¹Department of Internal Medicine, Korea University Anam Hospital, Seoul; ²Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul; ³Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon; ⁴Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju; ⁵Department of Internal Medicine and Digestive Disease Center, Seoul Medical Center, Seoul; ⁶Department of Internal Medicine and Research Institute of Clinical Medicine of Jeonbuk National University- Jeonbuk National University Hospital, Jeonju; ⁷Department of Pediatrics, Seoul Metropolitan Children’s Hospital, Seoul; ⁸Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan; ⁹Department of Internal Medicine, Gachon University Gil Medical Center, Incheon; ¹⁰Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu; ¹¹Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang; ¹²Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea

Procedural sedation has become increasingly common in endoscopy. Sedatives and analgesics induce anxiolysis and amnesia. In addition, an appropriate level of sedation is necessary for safe procedures including therapeutic endoscopy. Midazolam and propofol are the most commonly used drugs in sedative endoscopy. In recent years, the need to ascertain the safety and effectiveness of sedation has increased in practice. Therefore, new sedatives and analgesic drugs for optimal sedative endoscopy, have recently emerged. This article reviews the characteristics of sedatives and analgesics, and describes their clinical use in gastrointestinal endoscopy.

Keywords: Analgesics; Conscious sedation; Endoscopy; Hypnotics and sedatives

INTRODUCTION

Endoscopy plays a significant role in the diagnosis and treatment of gastrointestinal diseases. Sedation has been used in clinical practice to make the procedure more comfortable, and improve patient satisfaction by helping patients rest during the procedure. Although sedation is widely used for these benefits, it continues to pose some potential risks, requiring medical teams to closely monitor patients during the procedure. Currently, the most widely used agents for endoscopic sedation in Korea are midazolam and propofol.¹ Propofol is commonly used for intravenous anesthesia in outpatient surgeries and examinations, due to advantages such as rapid induction and early return of consciousness. However, propofol also has disadvantages as it decreases both cardiovascular and respiratory parameters and lacks antagonists.² The side effects of midazolam include hypoxemia, paradoxical responses, and delayed recovery. Therefore, there is a need for alternatives.³

Recently, newer sedatives that overcome these drawbacks have been discovered and subsequently applied in endoscopic
sedation. New drugs such as etomidate, dexmedetomidine, and remimazolam, have emerged, and the benefits of ketamine and remifentanil have also been highlighted. This review will therefore discuss etomidate and other new sedatives that are receiving attention in clinical practice.

**ETOMIDATE**

Etomidate is a short-acting intravenous anesthetic that is indicated for the induction of anesthesia and sedation during short procedures. It is an imidazole derivative that acts as a gamma-aminobutyric acid (GABA)-A receptor agonist in the central nervous system to induce sedation. The drug is mainly distributed by binding to albumin in blood plasma, inducing the opening of the chloride ion permeation channels of GABA-A receptors and amplifying the action of GABA for rapid sedation. Although etomidate is often compared with propofol, it was widely used in the field of general anesthesia even before the development of propofol. Its duration of action is slightly shorter than that of propofol because etomidate is redistributed to peripheral tissues such as muscles, and is metabolized by hepatic and plasma esterases. The resulting carboxylate metabolites are mostly excreted through the urine and bile, exhibiting an elimination half-life of 2–5 hours. Etomidate has an onset of action of 30–60 seconds, with peak effect at approximately 1 minute. Additionally, its action lasts for approximately 3–5 minutes, showing pharmacokinetic properties similar to those of propofol. When using etomidate, initial studies have recommended an induction dose of 0.1–0.2 mg/kg with additional 0.05 mg/kg every 3–5 minutes for maintenance. Although there are no dosage recommendations for etomidate in endoscopic sedation, sedation is mainly achieved using intermittent injections with an induction dose of 0.05 mg/kg, and additional 0.03–0.05 mg/kg for maintenance, in adult patients. In clinical practice, etomidate is mainly used in intensive care units and emergency medicine because it has a lower risk of respiratory depression or hypotension than other intravenous anesthetics. Thus, the advantages of etomidate include fast recovery, reduced impact on the cardiovascular system, and reduced respiratory failure. However, its disadvantages include pain associated with the injection as well as myoclonus. Additional administration of midazolam (0.015 mg/kg), magnesium sulfate, fentanyl (100–500 μg), or remifentanil (1 μg/kg) with etomidate may reduce the risk of myoclonus. The combination of propofol and etomidate can reduce the adverse effects of propofol or etomidate alone.

**DEXMEDITOMIDINE**

Dexmedetomidine is a highly selective α2 agonist used for sedation in various procedures. It is 7–8 times more selective for the α2 receptor than clonidine. It is an anxiolytic, sedative, and pain reliever with an elimination half-life of approximately 2 hours and a distribution half-life of approximately 6 minutes. Dexmedetomidine activates 2-adrenoceptors and causes a decrease in sympathetic tone, with associated attenuation of neuroendocrine and hemodynamic responses to anesthesia; it also reduces anesthetic and opioid requirements. There are several review articles and meta-analyses of dexmedetomidine in the field of endoscopic sedation. The usual dose used for sedation is 1 μg/kg for 6–10 minutes, followed by an intravenous infusion of 0.5–0.8 μg/kg/hr. However, some patients may require combined sedation with midazolam (0.5–1 mg). Dexmedetomidine is considered safe for administration to patients with spontaneous breathing, while ensuring that chin lift maneuvers are performed to maintain their stable breathing. Patients receiving dexmedetomidine are easy to arouse and are less likely to develop delirium than those receiving midazolam. However, it still has adverse effects, including bradycardia and hypotension. Therefore, caution should be exercised when administering it to patients with bradycardia, arrhythmia, heart failure, and/or hypotension. In some cases, maintenance doses are prescribed without a loading dose. Although dexmedetomidine has fewer adverse effects on respiratory function than propofol, it bears the risk of inducing insufficient sedation during endoscopic procedures. In summary, dexmedetomidine may be useful for diagnostic endoscopy; additional agents, such as midazolam or fentanyl, may be required for more time-consuming procedures such as therapeutic endoscopy. Considering all of these, dexmedetomidine was approved in December 1999 by the FDA as a short-term sedative and analgesic.

**REMIAMZOLAM**

Remimazolam is a short-acting benzodiazepine used to induce and maintain procedural sedation. Remimazolam modulated the effects of GABA-A receptors to enhance the effects of GABA. The half-life of remimazolam is not prolonged after

---

582
discontinuing continuous infusion. Therefore, the use of remimazolam as an analgesic in intensive care units offers some advantages over fentanyl. Unlike other sedatives that are mainly metabolized in the liver, remimazolam is metabolized by tissue esterases, regardless of their location in the body. Thus, it may be administered regardless of body weight, rapidly metabolizing in blood plasma and tissues. Remimazolam was observed to be well tolerated and effective after a single dose of 0.1–0.2 mg/kg or an initial dose of 5.0 mg during endoscopic procedures. If necessary, supplemental doses of 2.5 mg can be administered. However, at least 2 minutes must have elapsed after the initial dose, prior to the administration of any supplemental dose. Its onset of action is 1–3 minutes and its half-life is 7–8 minutes, which is slightly shorter than that of midazolam, and remains consistent even during continuous intravenous infusion. As such, patients recover quickly after discontinuation of remimazolam infusion. Notably, the benzodiazepine receptor antagonist flumazenil can be used to reverse the sedative effects associated with overdosing. Although the sedative efficiency of remimazolam is higher than that of midazolam, it is slightly lower than that of propofol. In a meta-analysis comparing remimazolam and midazolam, the remimazolam group showed excellent results in terms of procedure success rates, proper sedation maintenance, and use of antagonistic drugs. However, apnea or chest stiffness was observed in rare cases. In severe cases, chest or thoracic stiffness may affect jaw muscles. Remimazolam was approved for use by the FDA in July 2020; however, it should be used with caution, even during sedation, due to the risk of respiratory failure and hypoxia.

**KETAMINE**

Ketamine is a phencyclidine derivative that was first used in clinical practice in 1965. It is a rapid-acting general anesthetic and N-methyl-d-aspartate receptor antagonist. In terms of pharmacokinetics, ketamine fits a two-compartment model. Plasma concentration after intravenous infusion decreases rapidly at the early stage, which results in a slow elimination and distribution period that is suitable for endoscopy. Ketamine is mainly metabolized in the liver and its major metabolite is norketamine. It has an onset of action of less than 1 minute, reaching its peak effect at approximately 1 minute. Its action lasts for approximately 10–15 minutes, and the recommended induction dose is 0.5 mg/kg. Additional doses may be administered to patients after observing their degree of sedation. Ketamine is beneficial in preserving breathing and airway reflexes during endoscopy. The anesthetic state it produces has been termed “dissociative anesthesia” as it appears to selectively interrupt association pathways of the brain before producing a somesthetic sensory blockade. Ketamine also has anti-vagal effects; it increases the secretion of endogenous catecholamines, leading to excellent cardiopulmonary stability. Despite these advantages, the usefulness of ketamine as a sedative is limited because 10%–30% of patients experience hallucinations, visual distortions, and the sensation of floating during the recovery period. It is also associated with a 0.3% incidence of laryngospasms during endoscopic procedures. In the field of anesthesia, ketamine is usually administered with diazepam or midazolam. Currently, a combined administration of ketamine and midazolam is recommended for sedation rather than ketamine alone. In clinical practice, ketamine is considered as a useful drug with a low risk of apnea during pediatric sedation. The combination of midazolam and ketamine was most commonly used for pediatric endoscopic procedures. In procedural sedation for pediatric endoscopy, the sedation with midazolam 0.03 mg/kg + ketamine 0.65 mg/kg + propofol 2.5 mg/kg performed by an anesthesiologist was deeper and safer with fewer complications.

**FOSPROPOFOL**

Fospropofol is a sedative-hypnotic agent used for monitored sedation during anesthesia care. It is a water-soluble prodrug of propofol, which is metabolized into propofol, formaldehyde, and phosphate by endothelial alkaline phosphatase. Due to these pharmacokinetic properties, it exhibits the same rise in blood concentration as propofol. However, the effect of fospropofol persists for 15–30 minutes, and its excretion is slightly slower than that of propofol. Its disadvantages include the risk of cardiovascular and respiratory failure, which are similar to those of propofol. Additionally, side effects include itching and perineal pain. Some studies have been conducted on its use in endoscopic sedation, with one study attempting sedation with various concentrations (2, 5, 6.5, or 8 mg/kg) in colonoscopic procedures. This study showed a high success rate for moderate sedation in patients who received 6.5 mg/kg, and the results were positive in terms of doctor and patient satisfaction. Although the FDA approved the use of fospropofol in May 2008, it was later required in December 2008 that it be used only by individuals trained in the administration of general anesthesia.
### Table 1. Characteristics of sedative and analgesic drugs for gastrointestinal endoscopic procedure

| Drug        | Initial dose | Repeat dose      | Onset | Duration | Pros                                      | Cons                        | Reversal agent | Analgesic effect |
|-------------|--------------|------------------|-------|----------|-------------------------------------------|-----------------------------|----------------|------------------|
| Etomidate   | 0.15 mg/kg   | 0.05 mg/kg q 2 min | 30–60 sec | 3–5 min  | Fast onset of action                      | Myoclonus                   | -              | -                |
|             |              |                   |       |          | Hemodynamic stability                     | Adrenal suppression          |                |                  |
|             |              |                   |       |          | Low risk of respiratory depression        |                             |                |                  |
| Dexmedetomidine | 1 μg/kg   | Continuous infusion of 0.2–0.7 μg/μg/hr | 1 min | 2–4 hr   | Ability to preserve spontaneous ventilation | Slow onset and slow offset of effect | Atipamezole   | ++               |
| Remimazolam | 0.05–0.075 mg/kg | 0.2 mg/kg | 30–60 sec | 3–5 min  | Fast onset of action                      |                             |                |                  |
| Ketamine    | 1–2 mg/kg IV | 0.5 mg/kg q 2 min | 30–120 sec | 15–30 min | Analgesic effect                          | Hallucination                | -              | ++               |
|             |              |                   |       |          | Ability to preserve spontaneous ventilation| Increased salivation         |                |                  |
| Fospropofol | 6.5 mg/kg   | 1.6 mg/kg q 2 min | 4–8 min | 2–16 min | Aqueous formulation                       | Currently not available      |                | -                |
| Remifentanil| 0.1–0.3 μg/kg | 0.025–0.1 μg/μg/min | 30–60 sec | 3–6 min  | Hemodynamic stability                      | Naloxone                    | +++            |                  |
|             |              |                   |       |          | Low risk of respiratory depression        |                             |                |                  |
|             |              |                   |       |          | Short recovery time                        |                             |                |                  |
| Oliceridine | 1–3 mg      | 1 mg              | 5–20 min | 1–3 hr   | No dose adjustment                         | Slightly slow onset          | Naloxone       | +++              |
|             |              |                   |       |          | Low risk of respiratory depression        |                             |                |                  |

- none; +, weak; ++, moderate; +++; strong; IV, intravenous.

Remifentanil is a short-acting opioid analgesic and µ-opioid receptor agonist. It is metabolized by plasma and tissue esterases, and it has a short context-sensitive half-life of approximately 1–20 minutes. The metabolism of remifentanil is unaffected by changes in renal function, and it is easier to predict its clinical action and corresponding recovery period of the patient. It typically induces slight amnesic effects. The optimal induction dose of remifentanil is 0.1–0.2 μg/kg for 2 minutes, and its maintenance dose is 0.025–0.1 μg/kg/min. Administering 0.5–2 mg of midazolam 2–3 minutes before remifentanil administration may lead to better sedative and amnesic effects. Its sedative effect persists for 3–6 minutes, and several studies have shown that it is effective in reducing pain during endoscopy, especially when it is necessary for the patient to remain conscious during colonoscopy. Considering these, remifentanil was approved by the US FDA in July 1996.

Remifentanil is a short-acting opioid analgesic and µ-opioid receptor agonist. It is metabolized by plasma and tissue esterases, and it has a short context-sensitive half-life of approximately 1–20 minutes. The metabolism of remifentanil is unaffected by changes in renal function, and it is easier to predict its clinical action and corresponding recovery period of the patient. It typically induces slight amnesic effects. The optimal induction dose of remifentanil is 0.1–0.2 μg/kg for 2 minutes, and its maintenance dose is 0.025–0.1 μg/kg/min. Administering 0.5–2 mg of midazolam 2–3 minutes before remifentanil administration may lead to better sedative and amnesic effects. Its sedative effect persists for 3–6 minutes, and several studies have shown that it is effective in reducing pain during endoscopy, especially when it is necessary for the patient to remain conscious during colonoscopy.
with conventional opioids, including nausea, vomiting, respiratory failure, and/or constipation. Respiratory depression after administration of oliceridine is rare, particularly when using small doses. When administered with propofol as a sedative agent, it maintains sedation and reduces the required amount of propofol, thereby lowering the risk of cardiovascular side effects and respiratory failure. The combination of oliceridine and remimazolam is expected to have positive effects during colonoscopy. Its distribution tends to increase in patients with hepatic impairment, but this does not seem to have any effect on excretion. Therefore, oliceridine may be used in patients with hepatobiliary diseases. Oliceridine received the FDA’s breakthrough therapy designation in 2016 and was approved by the FDA in August 2020.

CONCLUSIONS

Table 1 summarized the characteristics of sedative and analgesic drugs for gastrointestinal endoscopic procedure.

Many endoscopists are looking for ideal drugs to be used in endoscopic sedation. Drugs such as etomidate, remimazolam, and dexmedetomidine may be useful for endoscopic sedation and may help improve procedural sedation in the future. However, it is also critical to understand the characteristics of these drugs and be aware of their strengths and risks in order to adequately prepare countermeasures. Considering the advantages and disadvantages of old and new drugs, it is necessary to have a thorough understanding of conventional drugs, before considering the introduction and application of new drugs, and to actively cope with recommended changes directed towards the most ideal sedation practice.

Conflicts of Interest

The authors have no potential conflicts of interest.

Funding

None.

Author Contributions

Conceptualization: JML, JKL, BWK; Data curation: YP, JMP, HHC, JYB; Formal analysis: HJP, JWC; Investigation: JML, YP, JYB; Methodology: JMP, SYS, JHL; Project administration: HJP, JWC, JKL, BWK; Resources: YP, JYB, SYS, JHL; Software: JWC, HKC, HHC; Supervision: JKL, BWK; Validation: HKC, SYS, JWC; Visualization: HJP, HKC, HHC; Writing—original draft: JML; Writing—review & editing: all authors.

ORCID

Jae Min Lee https://orcid.org/0000-0001-9553-5101
Yehyun Park https://orcid.org/0000-0001-8811-0631
Jin Myung Park https://orcid.org/0000-0002-8798-0587
Hong Jun Park https://orcid.org/0000-0001-9320-9978
Jun Yong Bae https://orcid.org/0000-0002-2501-5167
Seung Young Seo https://orcid.org/0000-0003-2018-0013
Lee Hyun Lee https://orcid.org/0000-0002-4318-2487
Hyung Ku Chon https://orcid.org/0000-0002-6068-3849
Jun-Won Chung https://orcid.org/0000-0002-0869-7661
Hyun Ho Choi https://orcid.org/0000-0003-0187-3842
Jun Kyu Lee https://orcid.org/0000-0002-2694-3598
Byung-Wook Kim https://orcid.org/0000-0002-2290-4954

REFERENCES

1. Conscious Sedation TFT Committee of KSGE. A guidebook on sedation for gastrointestinal endoscopy. Seoul: Medbook; 2015.
2. Training Committee. American Society for Gastrointestinal Endoscopy. Training guideline for use of propofol in gastrointestinal endoscopy. Gastrointest Endosc 2004;60:167–172.
3. Waring JP, Baron TH, Hirota WK, et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc 2003;58:317–322.
4. Goudra BG, Singh PM. Propofol alternatives in gastrointestinal endoscopy anesthesia. Anesthesiology 2011;114:695–707.
5. Han SJ, Lee TH, Yang JK, et al. Etomidate sedation for advanced endoscopic procedures. Dig Dis Sci 2019;64:144–151.
6. Lee JH, Min G, Lee JM, et al. Efficacy and safety of etomidate-midazolam for screening colonoscopy in the elderly: a prospective double-blinded randomized controlled study. Medicine (Baltimore) 2018;97:e10635.
7. Zhou X, Li BX, Chen LM, et al. Etomidate plus propofol versus propofol alone for sedation during gastroscopy: a randomized prospective clinical trial. Surg Endosc 2016;30:5108–5116.
8. Chen L, Liang X, Tan X, et al. Safety and efficacy of combined use of propofol and etomidate for sedation during gastroscopy: systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e15712.
11. Kim JH, Byun S, Choi YJ, et al. Efficacy and safety of etomidate in comparison with propofol or midazolam as sedative for upper gastrointestinal endoscopy. Clin Endosc 2020;53:555–561.

12. Scheinin H, Aantaa R, Anttila M, et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology 1998;89:574–584.

13. Liu W, Yu W, Yu H, et al. Comparison of clinical efficacy and safety between dexmedetomidine and propofol among patients undergoing gastrointestinal endoscopy: a meta-analysis. J Int Med Res 2021;49:300605211032786.

14. Chen YT, Sun CK, Wu KY, et al. The use of propofol versus dexmedetomidine for patients receiving drug-induced sleep endoscopy: a meta-analysis of randomized controlled trials. J Clin Med 2021;10:1585.

15. Nishizawa T, Suzuki H, Hosoe N, et al. Dexmedetomidine vs propofol for gastrointestinal endoscopy: a meta-analysis. United European Gastroenterol J 2017;5:1037–1045.

16. Nishizawa T, Suzuki H, Sagara S, et al. Dexmedetomidine versus midazolam for gastrointestinal endoscopy: a meta-analysis. Dig Endosc 2015;27:8–15.

17. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992;77:1125–1133.

18. Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000;90:699–705.

19. Jalowiecki P, Rudner R, Gonciarz M, et al. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology 2005;103:269–273.

20. Zhang F, Sun HR, Zheng ZB, et al. Dexmedetomidine versus midazolam for sedation during endoscopy: a meta-analysis. Exp Ther Med 2016;11:2519–2524.

21. Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting benzodiazipine. Anesthesiology 2007;107:60–66.

22. Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth 2014;8:388–991.

23. Borkett KM, Riff DS, Schwartz HI, et al. A phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg 2015;120:771–780.

24. Chen SH, Yuan TM, Zhang J, et al. Remimazolam tosylate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol 2021;36:474–481.

25. Zhu X, Wang H, Yuan S, et al. Efficacy and safety of remimazolam in endoscopic sedation—A systematic review and meta-analysis. Front Med (Lausanne) 2021;8:655042.

26. Jhuang BJ, Yeh BH, Huang YT, et al. Efficacy and safety of remimazolam for procedural sedation: a meta-analysis of randomized controlled trials with trial sequential analysis. Front Med (Lausanne) 2021;8:641866.

27. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965;6:279–291.

28. Cohen LB, Delegee MH, Aisenberg J, et al. AGA institute review of endoscopic sedation. Gastroenterology 2007;133:675–701.

29. Akbulut UE, Saylan S, Sengu B, et al. A comparison of sedation with midazolam-ketamine versus propofol-fentanyl during endoscopy in children: a randomized trial. Eur J Gastroenterol Hepatol 2017;29:112–118.

30. Eskander AE, Baroudy NR, Refay AS. Ketamine sedation in gastrointestinal endoscopy in children. Open Access Maced J Med Sci 2016;4:392–396.

31. Lee YM, Kang B, Kim YB, et al. Procedural sedation for pediatric upper gastrointestinal endoscopy in Korea. J Korean Med Sci 2021;36:e136.

32. Fechner J, Ihmsen H, Jeleazcov C, et al. Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol). Expert Opin Invest Drugs 2009;18:1565–1571.

33. Cohen LB. Clinical trial: a dose-response study of fospropofol disodium for moderate sedation during colonoscopy. Aliment Pharmacol Ther 2008;27:597–608.

34. Toklu S, Iyilikci L, Gonen C, et al. Comparison of etomidate-remifentanil and propofol-remifentanil sedation in patients scheduled for colonoscopy. Eur J Anaesthesiol 2009;26:370–376.

35. Mandel JE, Tanner JW, Lichtenstein GR, et al. A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopy. Anesth Analg 2008;106:434–439.

36. Fossler MJ, Sadler BM, Farrell C, et al. Oliceridine (TRV130), a novel G protein-biased ligand at the μ-opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. I: development of a pharmacokinetic/pharmacodynamic model. J Clin Pharmacol 2018;58:750–761.

37. Food and Drug Administration (FDA). FDA approved drug products: Olinvyk (Oliceridine) injection [Internet]. Silver Spring (MD): FDA; 2020 [cited 2022 Jan 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf.
38. Singla N, Minkowitz HS, Soergel DG, et al. A randomized, phase IIb study investigating oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res 2017;10:2413–2424.

39. Liang DY, Li WW, Nwaneshiudu C, et al. Pharmacological characters of oliceridine, a μ-opioid receptor G-protein-biased ligand in mice. Anesth Analg 2019;129:1414–1421.